Bristol-Myers Squibb (NYSE:BMY) - Aktienkurs, Nachrichten und Analyse

BMY Aktienübersicht

Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte.

Über das Unternehmen

BMY fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	3/6
Dividends	5/6

Belohnungen

Risikoanalyse

Die Dividende von 5.82% ist durch die Erträge nicht gut gedeckt

Hat einen hohen Schuldenstand

Narratives

Beta

Narratives bring a range of perspectives from our community.

Warren

Based on Analyst Price Targets

Expanding Oncology Portfolio and Advancing INDs Promise Bright Future for Revenue Growth and Net Margins

Increased investment in growth brands and successful commercialization of products like Breyanzi hint at significant...

Price at publication US$52.49

View narrative

Updated 18 Mar 2024

Bristol-Myers Squibb Company Wettbewerber

Zoetis

NYSE:ZTS

US$77.8b

Pfizer

NYSE:PFE

US$156.0b

Johnson & Johnson

NYSE:JNJ

US$350.3b

Teva Pharmaceutical Industries

NYSE:TEVA

US$19.4b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Bristol-Myers Squibb
Historical stock prices
Current Share Price	US$40.97
52 Week High	US$66.38
52 Week Low	US$39.91
Beta	0.43
1 Month Change	-6.95%
3 Month Change	-20.91%
1 Year Change	-38.07%
3 Year Change	-38.70%
5 Year Change	-10.31%
Change since IPO	1,817.43%

Aktuelle Nachrichten und Updates

Recent updates

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Feb 20

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Feb 06

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Feb 04

BMY: Might Be Approaching A Bottom In 2024

Jan 23

Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings

Jan 16

Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also

Jan 10

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation

Dec 31

Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60

Dec 26

Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now

Dec 19

Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock

Dec 12

Aktionärsrenditen

	BMY	US Pharmaceuticals	US Markt
7D	-3.8%	-0.5%	1.6%
1Y	-38.1%	16.6%	21.5%

Preisvolatilität

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: BMYDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: BMYDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Produkte für die Bereiche Hämatologie, Onkologie, Herz-Kreislauf, Immunologie, Fibrose und neurowissenschaftliche Erkrankungen an. Zu den Produkten des Unternehmens gehören Eliquis zur Verringerung des Risikos eines Schlaganfalls/einer systemischen Embolie bei nicht-valvulärem Vorhofflimmern und zur Behandlung von TVT/PE; Opdivo für verschiedene Krebsindikationen, darunter Blasen-, Blut-, Darmkrebs, Kopf- und Halskrebs, RCC, HCC, Lungenkrebs, Melanom, MPM, Magen- und Speiseröhrenkrebs; Pomalyst/Imnovid zur Behandlung des multiplen Myeloms; Orencia zur Behandlung von aktiver rheumatoider Arthritis und Psoriasis-Arthritis; und Sprycel zur Behandlung von Philadelphia-Chromosom-positiver chronisch-myeloischer Leukämie.

Bristol-Myers Squibb Company's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Bristol-Myers Squibb im Vergleich zum Marktanteil des Unternehmens?
BMY grundlegende Statistiken
Marktanteil	US$83.52b
Gewinn(TTM)	-US$6.15b
Umsatz(TTM)	US$45.53b

1.8x

Kurs-Umsatz-Verhältnis

-13.5x

Kurs-Gewinn-Verhältnis

Ist BMY zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BMY Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$45.53b
Kosten der Einnahmen	US$10.92b
Bruttogewinn	US$34.62b
Sonstige Ausgaben	US$40.77b
Umsatz	-US$6.15b

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

Jul 26, 2024

Gewinn per Aktie (EPS)	-3.03
Bruttomarge	76.03%
Nettogewinnspanne	-13.50%
Schulden/Eigenkapital-Verhältnis	336.7%

Wie hat sich BMY auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

5.9%

Aktuelle Dividendenrendite

-78%

Ausschüttungsquote

BMY Aktienübersicht

Belohnungen

Risikoanalyse

Expanding Oncology Portfolio and Advancing INDs Promise Bright Future for Revenue Growth and Net Margins

Bristol-Myers Squibb Company Wettbewerber

NYSE:ZTS

US$77.8b

NYSE:PFE

US$156.0b

NYSE:JNJ

US$350.3b

NYSE:TEVA

US$19.4b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Recent updates

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Is Not A Buy For Me

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Executive Chairman of the Board exercised options and sold US$3.6m worth of stock

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Fourth quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Full year 2023 earnings: EPS exceeds analyst expectations

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

BMY: Might Be Approaching A Bottom In 2024

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Erträge & Einnahmen